Gabapentin documents raise concerns about off-label promotion and prescribing

Australian Prescriber

Volumn 26, Issue 1, 2003, Pages 18-19

  Sweet, Melissa ^a  

^a Sweet Communication   (Australia)

Author keywords

Advertising; Pharmaceutical industry

Indexed keywords

GABAPENTIN;

ADVERTIZING; ALCOHOL WITHDRAWAL; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; FOCAL EPILEPSY; HUMAN; LAW SUIT; MIGRAINE; PRESCRIPTION; RESTLESS LEGS SYNDROME; SHORT SURVEY;

EID: 0037256802     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2003.010     Document Type: Short Survey

References (8)

1. Oncology/Hematology Associates of Centrat Illinois. http://www.ohaci.com/palm/trials/misc cancer_control_trials/N00CB_trials.htm
2. Neurontin (Gabapentin) - The illegat corporate creation of a blockbuster drug. Worst Pills, Best Pills 2002;8:36-8. http://www.citizen.org/
3. Update on the illegal promotion of Gabapentin (Neurontin). Worst Pills, Best Pills 2002;8:68-71. http://www.citizen.org/
4. Dinsdale P. Pfizer gets a public dressing down over promoting unlicensed drugs. Br Med J 2002;324:753.
5. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
6. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2(3 Pt 2):249-55.
7. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine [review]. CNS Drugs 2002; 16:611-34.
8. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.